Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is ...

Robert Blum. The likelihood now is that Cytokinetics will have to re-align itself around aficamten, currently in the SEQUOIA-HCM pivotal trial which is due to generate results later in 2023 ...

Cytokinetics has revealed the results from ... operations in anticipation of a launch in 2025. Chief executive Robert Blum said the near-term objective isn’t to switch patients from Camzyos ...

New England Patriots owner Robert Kraft is back. He is again addressing racism. He is again asking America to take a hard look at itself. He is again using America's biggest game as a vehicle to ...

The FBI released posters Tuesday seeking information about two senior Iranian intelligence officers involved in the disappearance of retired FBI Special Agent Robert Levinson as the agency is ...

Robert Kraft's team, the New England Patriots, might not have made it to play in Super Bowl LIX this year, but the team owner plans on being a presence during the game in a different, yet ...

HOLO-LAB: Searching. Searching… Found. An explorer who went to the South Pole, Robert Falcon Scott. FATIMA: Hi, Mr Scott, I’m Fatima. OLLIE: And I’m Ollie. ROBERT SCOTT: How do you do ...

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate ...

Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle. The ...

Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle. The company ...